|
|
Post by lakers on Dec 9, 2016 1:11:33 GMT -5
Afrezza + Tresiba Insulin Options (For a Guy Who Misses Doses and Miscalculates Carbs) Written by Mike Hoskins Published on November 25, 2016 www.healthline.com/diabetesmine/afrezza-and-tresiba-comboNovo execs must be reading the glowing review by Mike Hoskins. It begins to sink in me that Novo may acquire Mnkd after all for Afrezza, 12 TS pipeline, EpiHale, PAHale, CINV, Pain, RLS' CBD pipeline royalty, thousands of patents, and NOL. It's just a matter of when, not if. Novo would make Afrezza a long overdue blockbuster if they own it outright. No one can deny such a potent Afrezza+CGM+Tresiba (ACT) combo, not even AF, LDG. |
|
|
|
Post by sayhey24 on Dec 9, 2016 6:33:09 GMT -5
With Onduo on one side and IBM Watson on the other and start-ups like Vdex about ready to spring up, why does MNKD want to sell now unless the offered pps is huge?
|
|
|
|
Post by promann on Dec 9, 2016 7:00:11 GMT -5
With Onduo on one side and IBM Watson on the other and start-ups like Vdex about ready to spring up, why does MNKD want to sell now unless the offered pps is huge? I think $50.00 SP or more would be acceptable ! 🤑 |
|
|
|
Post by mockingjay on Dec 9, 2016 9:05:53 GMT -5
With Onduo on one side and IBM Watson on the other and start-ups like Vdex about ready to spring up, why does MNKD want to sell now unless the offered pps is huge? Below was the comment from the current CEO of Novo on Inhaled insulin in 2008 (and he was the one to decide to halt development of inhaled insulin in 2008) so there is no way that he will change his mind again . "Another inhaled insulin has gone up in smoke. Denmark’s Novo Nordisk, a leader in insulin, said it’s halting development of its AERx inhaled insulin system being developed in partnership with Aradigm. “Fast-acting inhaled insulin in the form it is known today is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices such as Novo Nordisk’s FlexPen,” Lars Rebien Sorensen, the company’s CEO, said in a press release. The drug was in the last lap of clinical testing. All patients in the phase III trial will be converted over to alternative treatments, the company said." |
|
|
|
Post by tw12 on Dec 9, 2016 9:46:55 GMT -5
www.reuters.com/article/us-novo-nordisk-ceo-idUSKCN1173S8HEALTH NEWS | Thu Sep 1, 2016 | 9:47am EDT Novo Nordisk's veteran CEO Lars Rebien Sorensen to step down By Annabella PultzNielsen | COPENHAGEN Novo Nordisk's long-serving chief executive Lars Rebien Sorensen is to step down early, it was announced on Thursday, at a time when the world's largest insulin maker has said it faces increased competition in the U.S. market where it generates about half its revenues. The company said Rebien Sorensen will be succeeded from January by Lars Fruergaard Jorgensen, currently executive vice president and head of corporate development. In addition the company's marketing chief, Jacob Riis, has been appointed as head of the North American business. Riis, who joined the company in 1996 and has previously been regarded by analysts as heir apparent to Rebien Sorensen, is currently executive vice president in charge of marketing and head of the China and Pacific sales regions. "We have unprecedented challenges in front of us in terms of competition and pricing environment, but we also have the best ever portfolio to compete with," said Jorgensen, who has been with the company for 25 years. Rebien Sorensen's departure appears to be a change of plan, the company having said in April 2015 that he would remain in his role until he approached the end of his contract, expiring in 2019.
|
|
|
|
Post by novafett on Dec 9, 2016 9:48:07 GMT -5
Below was the comment from the current CEO of Novo on Inhaled insulin in 2008 (and he was the one to decide to halt development of inhaled insulin in 2008) so there is no way that he will change his mind again . "Another inhaled insulin has gone up in smoke. Denmark’s Novo Nordisk, a leader in insulin, said it’s halting development of its AERx inhaled insulin system being developed in partnership with Aradigm. “Fast-acting inhaled insulin in the form it is known today is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices such as Novo Nordisk’s FlexPen,” Lars Rebien Sorensen, the company’s CEO, said in a press release. The drug was in the last lap of clinical testing. All patients in the phase III trial will be converted over to alternative treatments, the company said." A lot can happen in 8+ years. There's that  |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 9, 2016 10:31:05 GMT -5
Part of Novo holding down prices was looking to the future of reimbursement where they would get paid for improved patient outcomes. CGM is the only way to get enough data points to quantify patient outcomes. A1c, as an average blood glucose reading over 90 days won't speak to the incidences of hyper and hypo glycemia with the latter being the larger contributor to health complications people with diabetes suffer. Mike C alluded to CGMs in the last conference call and certainly he knows hooking up patients with CGMs is a great way to demonstrate Afrezza is a superior tool to treat diabetics with.
|
|
|
|
Post by slugworth008 on Dec 9, 2016 11:10:52 GMT -5
Afrezza + Tresiba Insulin Options (For a Guy Who Misses Doses and Miscalculates Carbs) Written by Mike Hoskins Published on November 25, 2016 www.healthline.com/diabetesmine/afrezza-and-tresiba-comboNovo execs must be reading the glowing review by Mike Hoskins. It begins to sink in me that Novo may acquire Mnkd after all for Afrezza, 12 TS pipeline, EpiHale, PAHale, CINV, Pain, RLS' CBD pipeline royalty, thousands of patents, and NOL. It's just a matter of when, not if. Novo would make Afrezza a long overdue blockbuster if they own it outright. No one can deny such a potent Afrezza+CGM+Tresiba (ACT) combo, not even AF, LDG. Well MNKD needs to do something to get over 300 scripts per week that's for damn sure. |
|
|
|
Post by lennymnkd on Dec 9, 2016 11:19:31 GMT -5
Well spoken / that is exactly what it is .
|
|
|
|
Post by cjm18 on Dec 9, 2016 11:23:25 GMT -5
With Onduo on one side and IBM Watson on the other and start-ups like Vdex about ready to spring up, why does MNKD want to sell now unless the offered pps is huge? Below was the comment from the current CEO of Novo on Inhaled insulin in 2008 (and he was the one to decide to halt development of inhaled insulin in 2008) so there is no way that he will change his mind again . "Another inhaled insulin has gone up in smoke. Denmark’s Novo Nordisk, a leader in insulin, said it’s halting development of its AERx inhaled insulin system being developed in partnership with Aradigm. “Fast-acting inhaled insulin in the form it is known today is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices such as Novo Nordisk’s FlexPen,” Lars Rebien Sorensen, the company’s CEO, said in a press release. The drug was in the last lap of clinical testing. All patients in the phase III trial will be converted over to alternative treatments, the company said." In the form it (inhaled Insulin) is in today. Today was 8 years ago. Today is afrezza. Mannkind needs cgms to be mainstream. |
|
|
|
Post by sportsrancho on Dec 9, 2016 14:04:16 GMT -5
Below was the comment from the current CEO of Novo on Inhaled insulin in 2008 (and he was the one to decide to halt development of inhaled insulin in 2008) so there is no way that he will change his mind again . "Another inhaled insulin has gone up in smoke. Denmark’s Novo Nordisk, a leader in insulin, said it’s halting development of its AERx inhaled insulin system being developed in partnership with Aradigm. “Fast-acting inhaled insulin in the form it is known today is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices such as Novo Nordisk’s FlexPen,” Lars Rebien Sorensen, the company’s CEO, said in a press release. The drug was in the last lap of clinical testing. All patients in the phase III trial will be converted over to alternative treatments, the company said." A lot can happen in 8+ years. There's that yes:-). People change their minds all the time when they want to be on the winning side of the trade. Case in point. Romney loves Trump now:-))) |
|
|
|
Post by lakers on Dec 9, 2016 15:19:19 GMT -5
m.4-traders.com/SANOFI-4698/news/Sanofi-New-Findings-on-Type-1-Diabetes-Mellitus-Described-by-Investigators-at-Sanofi-Aventis-Deuts-23522757/Here is the bombshell. Sanofi : New Findings on Type 1 Diabetes Mellitus Described by Investigators at Sanofi-Aventis Deutschland GmbH [Improving Efficacy of Inhaled Technosphere... 12/08/2016 | 06:14 pm New Findings on Type 1 Diabetes Mellitus Described by Investigators at Sanofi-Aventis Deutschland GmbH [Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of ...] By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Nutritional and Metabolic Diseases and Conditions - Type 1 Diabetes Mellitus have been published. According to news reporting originating in Frankfurt, Germany, by NewsRx journalists, research stated, "Technosphere ® insulin (TI), an inhaled human insulin with a fast onset of action, provides a novel option for the control of prandial glucose. We used the University of Virginia (UVA)/Padova simulator to explore in-silico the potential benefit of different dosing regimens on postprandial glucose (PPG) control to support the design of further clinical trials." The news reporters obtained a quote from the research from Sanofi-Aventis Deutschland GmbH, "Tested dosing regimens included at-meal or postmeal dosing, or dosing before and after a meal (split dosing). Various dosing regimens of TI were compared among one another and to insulin lispro in 100 virtual type-1 patients. Individual doses were identified for each regimen following different titration rules. The resulting postprandial glucose profiles were analyzed to quantify efficacy and the risk for hypoglycemic events. This approach allowed us to assess the benefit/risk for each TI dosing regimen and to compare results with simulations of insulin lispro. We identified a new titration rule for TI that could significantly improve the efficacy of treatment with TI." According to the news reporters, the research concluded: "In-silico clinical trials comparing the treatment effect of different dosing regimens with TI and of insulin lispro suggest that postmeal dosing or split dosing of TI, in combination with an appropriate titration rule, can achieve a superior postprandial glucose control while providing a lower risk for hypoglycemic events than conventional treatment with subcutaneously administered rapid-acting insulin products." For more information on this research see: Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator. Diabetes Technology & Therapeutics, 2016;18(9):574-585. Diabetes Technology & Therapeutics can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - http://www.liebertpub.com; Diabetes Technology & Therapeutics - www.liebertpub.com/overview/diabetes-technology-and-therapeutics/11/)Our news correspondents report that additional information may be obtained by contacting T. Klabunde, Sanofi Aventis Deutschland GmbH, D-65926 Frankfurt, Germany. Additional authors for this research include C. Giegerich, R. Jager, R. Dahmen, A. Boss, M. Grant, C. Dalla Man, C. Cobelli and T. Klabunde (see also Nutritional and Metabolic Diseases and Conditions - Type 1 Diabetes Mellitus). Keywords for this news article include: Frankfurt, Germany, Europe, Nutritional and Metabolic Diseases and Conditions, Insulin Dependent Diabetes Mellitus, Clinical Trials and Studies, Type 1 Diabetes Mellitus, Clinical Research, Peptide Proteins, Peptide Hormones, Proinsulin, Sanofi-Aventis Deutschland GmbH.
|
|
|
|
Post by kbrion77 on Dec 9, 2016 15:24:43 GMT -5
m.4-traders.com/SANOFI-4698/news/Sanofi-New-Findings-on-Type-1-Diabetes-Mellitus-Described-by-Investigators-at-Sanofi-Aventis-Deuts-23522757/Here is the bombshell. Sanofi : New Findings on Type 1 Diabetes Mellitus Described by Investigators at Sanofi-Aventis Deutschland GmbH [Improving Efficacy of Inhaled Technosphere... 12/08/2016 | 06:14 pm New Findings on Type 1 Diabetes Mellitus Described by Investigators at Sanofi-Aventis Deutschland GmbH [Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of ...] By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Nutritional and Metabolic Diseases and Conditions - Type 1 Diabetes Mellitus have been published. According to news reporting originating in Frankfurt, Germany, by NewsRx journalists, research stated, "Technosphere ® insulin (TI), an inhaled human insulin with a fast onset of action, provides a novel option for the control of prandial glucose. We used the University of Virginia (UVA)/Padova simulator to explore in-silico the potential benefit of different dosing regimens on postprandial glucose (PPG) control to support the design of further clinical trials." The news reporters obtained a quote from the research from Sanofi-Aventis Deutschland GmbH, "Tested dosing regimens included at-meal or postmeal dosing, or dosing before and after a meal (split dosing). Various dosing regimens of TI were compared among one another and to insulin lispro in 100 virtual type-1 patients. Individual doses were identified for each regimen following different titration rules. The resulting postprandial glucose profiles were analyzed to quantify efficacy and the risk for hypoglycemic events. This approach allowed us to assess the benefit/risk for each TI dosing regimen and to compare results with simulations of insulin lispro. We identified a new titration rule for TI that could significantly improve the efficacy of treatment with TI." According to the news reporters, the research concluded: "In-silico clinical trials comparing the treatment effect of different dosing regimens with TI and of insulin lispro suggest that postmeal dosing or split dosing of TI, in combination with an appropriate titration rule, can achieve a superior postprandial glucose control while providing a lower risk for hypoglycemic events than conventional treatment with subcutaneously administered rapid-acting insulin products." For more information on this research see: Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator. Diabetes Technology & Therapeutics, 2016;18(9):574-585. Diabetes Technology & Therapeutics can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - http://www.liebertpub.com; Diabetes Technology & Therapeutics - www.liebertpub.com/overview/diabetes-technology-and-therapeutics/11/)Our news correspondents report that additional information may be obtained by contacting T. Klabunde, Sanofi Aventis Deutschland GmbH, D-65926 Frankfurt, Germany. Additional authors for this research include C. Giegerich, R. Jager, R. Dahmen, A. Boss, M. Grant, C. Dalla Man, C. Cobelli and T. Klabunde (see also Nutritional and Metabolic Diseases and Conditions - Type 1 Diabetes Mellitus). Keywords for this news article include: Frankfurt, Germany, Europe, Nutritional and Metabolic Diseases and Conditions, Insulin Dependent Diabetes Mellitus, Clinical Trials and Studies, Type 1 Diabetes Mellitus, Clinical Research, Peptide Proteins, Peptide Hormones, Proinsulin, Sanofi-Aventis Deutschland GmbH. Does this really need to be posted again? |
|
|
|
Post by papanigon on Dec 9, 2016 15:25:53 GMT -5
That is good news/research. If the pps goes down to what analyst project, I will be baffled.
|
|
|
|
Post by promann on Dec 9, 2016 15:45:35 GMT -5
This is great news!! Great work with the reporters and Mary Ann Liebert INC. to your credit I'm happy you chose to write about a great medicine to treat Diabetes AFREZZA !!
Thank You very much for sharing this Article...
|
|
